for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Vertex Pharmaceuticals Incorporated

VRTX.OQ

Latest Trade

187.52USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

185.37

 - 

306.08

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Health Canada Grants Marketing Authorization For Trikafta In People Ages 12 And Older Who Have At Least One F508del Mutation

June 18 (Reuters) - Vertex Pharmaceuticals Inc <VRTX.O>::HEALTH CANADA GRANTS MARKETING AUTHORIZATION FOR TRIKAFTA® (ELEXACAFTOR/TEZACAFTOR/IVACAFTOR AND IVACAFTOR) IN PEOPLE AGES 12 AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION.

Vertex Announces Primary Endpoint Achieved In Phase 2 Study Of VX-864

June 10 (Reuters) - Vertex Pharmaceuticals Inc <VRTX.O>::VERTEX ANNOUNCES PRIMARY ENDPOINT ACHIEVED IN PHASE 2 STUDY OF VX-864 IN ALPHA-1 ANTITRYPSIN DEFICIENCY.VERTEX PHARMACEUTICALS INC - TREATMENT WITH VX-864 LED TO STATISTICALLY SIGNIFICANT INCREASE FROM BASELINE IN PLASMA FUNCTIONAL AAT LEVELS VERSUS PLACEBO.VERTEX PHARMACEUTICALS INC - TREATMENT WITH VX-864 WAS GENERALLY WELL TOLERATED.VERTEX PHARMACEUTICALS INC - TO ADVANCE ADDITIONAL NOVEL SMALL MOLECULE(S) WITH POTENTIAL FOR GREATER CLINICAL EFFICACY INTO CLINIC IN 2022.VERTEX PHARMACEUTICALS INC - MAGNITUDE OF TREATMENT EFFECT OBSERVED IN THIS STUDY IS UNLIKELY TO TRANSLATE INTO SUBSTANTIAL CLINICAL BENEFIT.VERTEX PHARMACEUTICALS INC - WILL NOT ADVANCE VX-864 INTO LATE-STAGE DEVELOPMENT.

Vertex Announces U.S. FDA Approval For Trikafta® (Elexacaftor/Tezacaftor/Ivacaftor And Ivacaftor) In Children With Cystic Fibrosis Ages 6 Through 11 With Certain Mutations

June 9 (Reuters) - Vertex Pharmaceuticals Inc <VRTX.O>::VERTEX ANNOUNCES U.S. FDA APPROVAL FOR TRIKAFTA® (ELEXACAFTOR/TEZACAFTOR/IVACAFTOR AND IVACAFTOR) IN CHILDREN WITH CYSTIC FIBROSIS AGES 6 THROUGH 11 WITH CERTAIN MUTATIONS.VERTEX PHARMACEUTICALS INC - AN ADDITIONAL DOSAGE STRENGTH OF TRIKAFTA TABLETS IS NOW AVAILABLE IN CONNECTION WITH APPROVAL.VERTEX -WITH APPROVAL, ABOUT 1,500 CHILDREN WITH 1 MINIMAL FUNCTION MUTATION, ONE F508DEL MUTATION HAVE MEDICINE TO TREAT UNDERLYING CAUSE OF DISEASE.

Vertex And Obsidian Therapeutics Establish Collaboration To Discover Novel Therapies That Regulate Gene Editing

April 22 (Reuters) - Vertex Pharmaceuticals Inc <VRTX.O>::VERTEX AND OBSIDIAN THERAPEUTICS ESTABLISH COLLABORATION TO DISCOVER NOVEL THERAPIES THAT REGULATE GENE EDITING.VERTEX PHARMACEUTICALS INC - WILL PAY OBSIDIAN UP TO $75 MILLION IN EQUITY, UPFRONT PAYMENTS AND POTENTIAL RESEARCH MILESTONES.VERTEX PHARMACEUTICALS INC - OBSIDIAN IS ELIGIBLE TO RECEIVE UP TO $1.3 BILLION IN POTENTIAL PAYMENTS.VERTEX PHARMACEUTICALS INC - SPECIFIC DISEASES THAT ARE SUBJECT OF COLLABORATION ARE NOT DISCLOSED.

Vertex Pharma And Crispr Amend Collaboration For Development, Manufacturing And Commercialization Of CTX001 In Sickle Cell Disease And Beta Thalassemia

April 20 (Reuters) - Vertex Pharmaceuticals Inc <VRTX.O>::VERTEX PHARMA AND CRISPR AMEND COLLABORATION FOR DEVELOPMENT, MANUFACTURING AND COMMERCIALIZATION OF CTX001 IN SICKLE CELL DISEASE AND BETA THALASSEMIA.VERTEX PHARMACEUTICALS INC - REVISED AGREEMENT PROVIDES VERTEX WITH 60% AND CRISPR WITH 40% OF PROGRAM ECONOMICS.VERTEX PHARMA - CRISPR TO RECEIVE $900 MILLION UPFRONT PAYMENT WITH POTENTIAL FOR ADDITIONAL $200 MILLION MILESTONE PAYMENT UPON CTX001 APPROVAL.VERTEX PHARMACEUTICALS INC - VERTEX TO LEAD WORLDWIDE DEVELOPMENT, MANUFACTURING AND COMMERCIALIZATION OF CTX00.

Vertex Announces FDA Fast Track Designation For VX-880

March 10 (Reuters) - Vertex Pharmaceuticals Inc <VRTX.O>::VERTEX ANNOUNCES FDA FAST TRACK DESIGNATION AND INITIATION OF A PHASE 1/2 CLINICAL TRIAL FOR VX-880, A NOVEL INVESTIGATIONAL CELL THERAPY FOR THE TREATMENT OF TYPE 1 DIABETES.

Vertex Reports Full-Year And Fourth-Quarter 2020 Financial Results

Feb 1 (Reuters) - Vertex Pharmaceuticals Inc <VRTX.O>::VERTEX REPORTS FULL-YEAR AND FOURTH-QUARTER 2020 FINANCIAL RESULTS.COMPANY PROVIDES FULL-YEAR 2021 PRODUCT REVENUE GUIDANCE OF $6.7 TO $6.9 BILLION.QTRLY NON-GAAP NET INCOME PER SHARE $2.51.QTRLY GAAP NET INCOME PER SHARE $2.30.QTRLY NET GAAP PRODUCT REVENUES $1.63 BILLION VERSUS $1.41 BILLION.Q4 EARNINGS PER SHARE VIEW $2.59, REVENUE VIEW $1.58 BILLION -- REFINITIV IBES DATA.

Vertex Announces FDA Clearance Of Investigational New Drug Application For Cell Therapy To Treat Type 1 Diabetes

Jan 28 (Reuters) - Vertex Pharmaceuticals Inc <VRTX.O>::VERTEX ANNOUNCES FDA CLEARANCE OF INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR VX-880, A NOVEL CELL THERAPY FOR THE TREATMENT OF TYPE 1 DIABETES (T1D).VERTEX PHARMACEUTICALS INC - WILL INITIATE A PHASE 1/2 CLINICAL TRIAL IN FIRST HALF OF 2021.

Skyhawk And Vertex Collaborate To Discover, Develop Small Molecules For Serious Diseases

Dec 22 (Reuters) - Vertex Pharmaceuticals Inc <VRTX.O>::SKYHAWK AND VERTEX ESTABLISH A STRATEGIC COLLABORATION TO DISCOVER AND DEVELOP NOVEL SMALL MOLECULES THAT MODULATE RNA SPLICING FOR SERIOUS DISEASES.VERTEX PHARMACEUTICALS INC - SKYHAWK RECEIVES $40 MILLION UPFRONT AS WELL AS POTENTIAL MILESTONES AND ROYALTY PAYMENTS ON FUTURE SALES.VERTEX PHARMACEUTICALS INC - VERTEX RECEIVES EXCLUSIVE OPTIONS TO LICENSE A NUMBER OF SKYHAWK'S PRODUCT CANDIDATES DIRECTED AT SERIOUS DISEASES.VERTEX - SKYHAWK IS ALSO ELIGIBLE TO RECEIVE UP TO $2.2 BILLION IN POTENTIAL MILESTONE PAYMENTS, AS WELL AS POTENTIAL ROYALTIES ON FUTURE SALES.

Vertex Announces FDA Approvals Of Trikafta, Symdeko & Kalydeco For Use In People With CF With Certain Rare Mutations

Dec 21 (Reuters) - Vertex Pharmaceuticals Inc <VRTX.O>::VERTEX ANNOUNCES FDA APPROVALS OF TRIKAFTA® (ELEXACAFTOR/TEZACAFTOR/IVACAFTOR AND IVACAFTOR), SYMDEKO® (TEZACAFTOR/IVACAFTOR AND IVACAFTOR) AND KALYDECO® (IVACAFTOR) FOR USE IN PEOPLE WITH CF WITH CERTAIN RARE MUTATIONS.VERTEX PHARMACEUTICALS - EXPANDED ELIGIBILITY FOR TRIKAFTA TO INCLUDE PEOPLE WITH CF AGES 12 YEARS, OLDER WITH CERTAIN MUTATIONS IN CFTR GENE.VERTEX PHARMACEUTICALS - SYMDEKO ALSO RECEIVED APPROVAL TO INCLUDE ADDITIONAL RESPONSIVE MUTATIONS IN PEOPLE WITH CF AGES 6 YRS & OLDER.VERTEX PHARMACEUTICALS - KALYDECO ALSO RECEIVED APPROVAL TO INCLUDE ADDITIONAL RESPONSIVE MUTATIONS IN PEOPLE WITH CF AGE 4 MONTHS & OLDER.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up